公司股东昆山伟裕商务咨询有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本 公 司 及 董 事 会 全 体 成 员 保 证 公 告 内 容 与 信 息 披 露 义 务 人 提供的 信息一致。 优德精密工业（昆山）股份有限公司（以下简称"公司"）于2025年11月03 日披露了《关于公司高级管理人员减持股份的预披露公告》（公告编号：2025-044）。 昆山伟裕商务咨询有限公司计划以集中竞价方式减持公司股份不超过62,500股， 占本公司总股本0.047%。 近日，公司收到上述股东的《关于股份减持计划期限届满告知函》，根据《上 市公司股东减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第 18号——股东及董事、监事、高级管理人员减持股份》等相关规定，现将其减持 计划实施情况公告如下： 一、股东减持情况 1.股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 减持比 | | | --- | --- | --- | --- | --- | --- | --- | | | | | （元/股） | (股) | 例(%) | | ...

Group 1 - Fangda Carbon plans to acquire 100% equity of Tianjin Tongda Huanyu Logistics Co., Ltd. for 319 million yuan [1] - Xiamen Tungsten intends to acquire 39% equity of Jiujiang Dadi Mining Development Co., Ltd. and has signed an intention agreement with a transferor [6] - Wenkai Co. has won a bid for a landscape project worth 50.8162 million yuan [7] Group 2 - Changchun High-tech's subsidiary Jin Sai Pharmaceutical received approval for a clinical trial application for GenSci136, a treatment for IgA nephropathy [3] - China National Pharmaceutical has received drug registration certificates for fumaric acid volnoral tablets, used for treating reflux esophagitis [12] - Zhenhua Group plans to issue convertible bonds not exceeding 1.2 billion yuan [26] Group 3 - CSG Holding's stock may undergo a control change due to share pledge judicial transfer [30] - Ningbo Yunsheng plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [19] - Keda Guochuang's controlling shareholder intends to transfer 5% of the company's shares through an agreement [28] Group 4 - A number of companies, including Finer Pharma, Yixing Guoyuan Investment, and others, have announced plans to reduce their shareholdings by various percentages [2][4][9][11][15][16][20][21][22][23][25][29] - Highweida plans to repurchase shares worth 30 to 35 million yuan [17] - ST Zhongzhu is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [24] Group 5 - A number of companies, including Jiekang Equipment and others, have faced legal issues or penalties [27][40] - Aclaris Therapeutics has clarified that reports regarding its robotic products entering mass production were misinterpreted [41]

Group 1 - The controlling shareholder of Bowei Alloy plans to increase its stake in the company by 100 million to 150 million yuan [1] - The actual controller and directors of Congsheng Co. intend to reduce their holdings by no more than 5% of the company's shares [1] - Yinbei Investment of Senba Sensor plans to reduce its stake by no more than 3% of the company's shares [1] Group 2 - The controlling shareholder and its concerted parties of Liansheng Chemical plan to reduce their holdings by no more than 3% of the company's shares [1] - A shareholder of ST Zhongzhu intends to reduce its stake by no more than 3% of the company's shares [1] - Shareholders of Youde Precision (rights protection) plan to collectively reduce their holdings by no more than 3% of the company's shares [1] Group 3 - Shareholder Finer of Xuantai Pharmaceutical plans to reduce its stake by no more than 2% of the company's shares [1] - A shareholder of Far East Co. intends to reduce its holdings by no more than 1.5% of the company's shares [1] - A shareholder of Zhongzhou Special Materials plans to reduce its stake by no more than 1.4% of the company's shares [1] Group 4 - Qianhai Jin控 plans to reduce its stake in GCL-Poly Energy by no more than 1.01% of the company's shares [1] - The controlling shareholder of Keda Technology intends to reduce its holdings by no more than 1% of the company's shares [1] - Yulong Venture Capital plans to reduce its stake in Haiguo Co. by no more than 0.9965% of the company's shares [1] Group 5 - Shareholders of Lian Technology plan to collectively reduce their holdings by no more than 0.96% of the company's shares [1] - The controlling shareholder of Teda Co. intends to reduce its holdings by no more than 29.38 million shares [1] - The actual controller of Perfect World reduced its stake by 1.247 million shares during a period of abnormal stock fluctuations [1] Group 6 - A shareholder of Tengya Precision plans to reduce its stake by no more than 3.8 million shares [1]

Group 1 - Jinwei Co., Ltd. plans to acquire 100% equity of Fusheng Mining for 210 million yuan, which will become a wholly-owned subsidiary and included in the consolidated financial statements [2] - Mengguli intends to invest 929 million yuan to build a project with an annual production capacity of 30,000 tons of lithium-ion battery cathode materials, expected to produce 5,000 tons of high-voltage cobalt acid lithium, 10,000 tons of NCA materials, and 15,000 tons of ultra-high nickel ternary materials [2] - Xiamen Tungsten plans to acquire 39% equity of Jiujiang Dadi Mining, which will help increase mineral resource reserves and improve raw material self-sufficiency [3] Group 2 - Andavil's subsidiary received EASA certification for its aviation kitchen plug-in products, marking compliance with European aviation safety standards [2] - CIMC Vehicles disclosed that the US ITC made a preliminary ruling on anti-subsidy and anti-dumping investigations regarding Van-Type Trailers, indicating potential damage to the US domestic industry [4] - Source Technology plans to invest approximately 1.251 billion yuan to build a second phase project for the R&D and production of optoelectronic communication semiconductor chips and devices [9] Group 3 - Zhongmin Energy intends to acquire 51% equity of Mintou Pumped Storage for 864 million yuan, with the transaction price based on asset evaluation [10] - Ningbo Yunsheng plans to publicly issue H-shares and apply for listing on the Hong Kong Stock Exchange [11] - Wenkai Co., Ltd. won a bid for a landscape project worth 50.8162 million yuan [12] Group 4 - China Merchants Shekou achieved a signed sales amount of 7.674 billion yuan in January 2026 [16] - AVIC Optoelectronics reported a net profit of 2.124 billion yuan for 2025, a year-on-year decrease of 36.69% [17] - Tiankang Bio reported a sales revenue of 392 million yuan from pig sales in January 2026, with a month-on-month increase of 6.23% [18] Group 5 - Poly Developments reported a signed amount of 15.617 billion yuan in January 2026, a year-on-year decrease of 13.31% [19] - Chengtou Holdings reported a net profit of 290 million yuan for 2025, a year-on-year increase of 19.67% [20] - Qianjin Pharmaceutical reported a net profit of 288 million yuan for 2025, a year-on-year increase of 24.74% [21]

格隆汇2月9日丨优德精密(300549.SZ)公布，接到股东United Creation Management Limited（简 称"UCM"）的通知。UCM计划在本公告发布后的15个交易日起的3个月内（2026年03月11日至2026年06 月10日），通过集中竞价交易（盘后定价）方式减持不超过1%股份，通过大宗交易方式减持不超过2% 股份。 ...

智通财经APP讯，优德精密(300549.SZ)发布公告，近日，公司接到股东UnitedCreation Management Limited(以下简称"UCM")的通知。 UCM计划在本公告发布后的15个交易日起的3个月内(2026年03月11 日至2026年06月10日)，通过集中竞价交易(盘后定价)方式减持不超过133.34万股公司股份，占公司总股 本的1%，通过大宗交易方式减持不超过266.68万股，占公司总股本的2%。 ...

优德精密（300549）(300549.SZ)发布公告，近日，公司接到股东UnitedCreation Management Limited(以 下简称"UCM")的通知。UCM计划在本公告发布后的15个交易日起的3个月内(2026年03月11日至2026年 06月10日)，通过集中竞价交易(盘后定价)方式减持不超过133.34万股公司股份，占公司总股本的1%， 通过大宗交易方式减持不超过266.68万股，占公司总股本的2%。 ...

（记者 王晓波） 每经AI快讯，优德精密2月9日晚间发布公告称，近日，公司接到股东United Creation Management Limited的通知。UCM计划在本公告发布后的15个交易日起的3个月内（2026年3月11日至2026年6月10 日），通过集中竞价交易（盘后定价）方式减持不超过约133万股公司股份，占公司总股本的1%，通过 大宗交易方式减持不超过约267万股，占公司总股本的2%。 每经头条（nbdtoutiao）——美国名校毕业刚回国，26岁"金少"空降成董事长和总经理，父母隐退！A股 多位"00后"执掌要职，"不负投资者"成重大考验 ...

证券代码：300549 证券简称：优德精密 公告编号：2026-002 | 序 | 股东名称 | | 持股数量（股） | 占本公司总股 | 无限售流通股 | 无限售流通股份数量 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | 份比例 | | 占公司总股本比例 | | 1 | United Management | Creation | 17,992,000 | 13.49% | 17,992,000 | 13.49% | | | Limited | | | | | | 二、本次减持计划的主要内容 1、减持原因：公司经营需要。 2、减持股份来源：公司首次公开发行前的股份，以及公司资本公积金转增股本方式取得 的股份。 3、拟减持方式、数量、比例、价格 | 股东名称 | | 计划减持数量 （股） | 占本公司 总股份比 | 减持方式 | 减持价格 | | --- | --- | --- | --- | --- | --- | | | | | 例 | | | | United Management | Creation Limited | 1,333 ...

Performance Forecast - The company has voluntarily announced a performance forecast for the period from January 1, 2025, to December 31, 2025, indicating a projected decline in performance [1] - The company expects a year-on-year revenue decline of approximately 9% due to operational pressures in its main automotive mold components business [1] Reasons for Performance Change - The decline in revenue is attributed to increased procurement costs from imported raw materials due to tariff hikes, coupled with intensified competition in the domestic automotive mold components market, leading to reduced sales and revenue [1] - Although the medical device components and automation components segments experienced year-on-year growth, this growth was insufficient to offset the decline in the automotive mold components business, resulting in an overall decrease in performance [1] Financial Risk Management - The company is focusing on financial risk prevention by enhancing the management of accounts receivable, implementing a customer credit assessment mechanism, and strengthening the tracking of payment processes, with no significant bad debts reported during the period [2] Additional Information - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited [3] - Detailed performance data for 2025 will be disclosed in the company's annual report for that year [3]